Claim your 1.0hr CE/CME Credit Here
Name
*
First Name
Last Name
Email
*
example@example.com
What best describes your title?
*
MD/DO
RN/NP
PA
PharmD/RPh
Respiratory Therapist
Non-Clinician Research Coordinator
Other
If MD/DO
medical oncologist
surgical oncologist
radiation oncologist
hematologist
other internist
hospitalist
primary care provider
emergency medicine
Other
If RN/NP
NPP
ICU
cath lab
ward
clinic
academic
industry
Other
If PharmD
hospital/health system-based
community
academic
industry
Other
Where are you based?
EU/GB
Canada
USA
Latin America
Australia/NZ
Asia
How did you FIRST hear about our tweetorials?
found it on Twitter searching in subject area
found it on twitter searching for CE/CME
found it on Twitter by following individual influencer
found it on Twitter by following institutional influencer
from LinkedIn
How many years have you been in practice?
How many patients per month do you typically see with the disease addressed in this tweetorial?
1. Luspatercept, now with updated Phase 3 INDEPENDENCE data at EHA2026 in myelofibrosis-associated anemia, is best described as which of the following?
*
A. EPO receptor agonist
B. JAK2 kinase inhibitor
C. Activin receptor trap
D. Anti-mCALR antibody
2. Why add uspatercept to an ongoing JAKi (ruxolitinib, fedratinib) in MF-associated anemia? The key biologic rationale is . . .
*
A. JAKi suppress SMAD2/3
B. JAKi worsen anemia
C. Boosts anti-fibrotic effect
D. Prevents JAKi thrombosis
3. At EHA2026, Passamonti presented updated primary results of Phase 3 INDEPENDENCE ([luspatercept + JAKi] vs [placebo + JAKi] in transfusion-dependent MF anemia). What was the headline finding for the primary RBC-TI endpoint?
*
A. Met, p<0.001
B. Narrow miss, p=0.0674
C. No difference vs placebo
D. Halted early for futility
4. In the updated EHA2026 INDEPENDENCE analysis, luspatercept benefit was consistent across most subgroups EXCEPT which one?
*
A. DIPSS Int-2/high risk
B. On ruxolitinib
C. APAC region / sEPO ≥500
D. JAK2 V617F mutated
5. Did you follow the entire tweetorial?
*
Yes
No
6. Did you find this to be an effective learning tool?
*
Yes
No
7. On a scale of 1 to 5, how applicable to your clinical practice was the material in this tweetorial?
*
Not At All Pertinent
1
2
3
4
Extremely Pertinent
5
1 is Not At All Pertinent, 5 is Extremely Pertinent
8. How will this program change your practice?
*
Not pertinent to my practice
Reinforces my practice
Makes me want additional education
Will change my practice
9. Will you recommend @ONC_CE and/or this website to your colleagues?
*
Yes
No
-
Month
-
Day
Year
2 digit month, 2 digit day, 4 digit year
Date
Title of Course
Claim Certificate
Should be Empty: